Document is current

Article History

Received: 13 April 2021

Accepted: 28 June 2021

First Online: 27 July 2021

Declarations

:

: P. Hendrix, M. Killer-Oberpfalzer, E. Broussalis, I. Melamed, V. Sharma, S. Mutzenbach, S. Pikija, M. Collins, N. Lieberman, C. Hecker, O. Goren, R. Zand, C.M. Schirmer, E. Trinka, and C.J. Griessenauer declare that they have no competing interests. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. C.J. Griessenauer has acted as consultant to Stryker and Microvention and received research funding from Medtronic and Penumbra. E. Trinka reports personal fees from EVER Pharma, Marinus, Argenix, Arvelle, Medtronic, Bial-Portela & Cª, S.A., NewBridge, GL Pharma, GlaxoSmithKline, Hikma, Boehringer Ingelheim, LivaNova, Eisai, UCB, Biogen, Genzyme Sanofi, GW Pharmaceuticals, and Actavis outside the submitted work; his institution received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF <i>Osterreichischer Fond zur Wissenschaftsforderung, Bundesministerium für Wissenschaft und Forschung</i>, and <i>Jubilaumsfond der Österreichischen Nationalbank</i> outside the submitted work.

: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval: IRB approval for this retrospective analysis was obtained. Consent to participate: waived for retrospective analysis.